Oxford, UK – 11 October 2016. OGT, The Molecular Genetics Company, has today announced a significant expansion of its existing catalog of CytoCell® Hematology probes for fluorescence in situ hybridization (FISH) — underlining the company's position as the one-stop-shop for high-quality FISH probes. These additions have been introduced due to an ongoing commitment to use customer input as a major driver for the rapid development of the latest research-relevant probes. The 14 newly launched probes are:
The new cost-effective and quality-assured probes are optimized for use on common sample types and are sold as pre-mixed, easy-to-use formulations to minimize experimental errors. The importance of researchers’ input in today’s announcement demonstrates the ongoing success of OGT’s myProbes® service, which enables scientists to order custom-made probes for virtually any sequence in the human genome. All probes are produced under GMP/GLP guidelines using the CytoCell BAC-2-FISH™ process, combining high-intensity signals with low levels of background fluorescence and providing maximum confidence in results.
As the longest-standing FISH probe manufacturer in the world, 2016 marks 25 years of CytoCell expertise and customer service in the development and production of FISH products. “myProbes gives us the opportunity to get continuous input from our customers,” explains Faidra Partheniou, Hematology Product Manager at OGT, “it truly helps us to respond quickly to changes in customer demand and it helps researchers by providing a first port of call for rapid development of new probes. These latest additions to our CytoCell portfolio are testament to this.”
OGT also offers the opportunity to evaluate the accurate, user-friendly FISH probes in customer’s own labs free of charge by simply requesting up to four free probes from their extensive range.
The new additions to the CytoCell hematology probe range are currently only available within North America as analyte specific reagents (ASRs), analytical and performance characteristics are not established. CE-marked IVD versions for sale in Europe are anticipated.
Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read
State-of-the-art premises increases operational footprint and will host Sysmex global R&D facility.
Read
Plasma and tissue sequencing demonstrate clearance of ctDNA correlates with pathologic complete response in breast cancer patients during neoadjuvant treatment.
Read
Visit International site
Visit Canada site
International
